Literature DB >> 28775503

LOW MOLECULAR WEIGHT HEPARINS.

S K Sharma1.   

Abstract

Entities:  

Year:  2017        PMID： 28775503      PMCID： PMC5531654          DOI： 10.1016/S0377-1237(17)30571-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN： 0377-1237


× No keyword cloud information.
  6 in total

Review 1.  Low-molecular-weight heparins.

Authors:  J I Weitz
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

2.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

3.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

4.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

5.  A meta-analysis of methods to prevent venous thromboembolism following total hip replacement.

Authors:  T F Imperiale; T Speroff
Journal:  JAMA       Date:  1994-06-08       Impact factor: 56.272

6.  Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.

Authors:  A W Lensing; M H Prins; B L Davidson; J Hirsh
Journal:  Arch Intern Med       Date:  1995-03-27
  6 in total
  2 in total

1.  Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model.

Authors:  Conor McCafferty; Leo Lee; Tengyi Cai; Slavica Praporski; Julian Stolper; Vasiliki Karlaftis; Chantal Attard; David Myint; Leeanne M Carey; David W Howells; Geoffrey A Donnan; Stephen Davis; Henry Ma; Sheila Crewther; Vinh A Nguyen; Suelyn Van Den Helm; Natasha Letunica; Ella Swaney; David Elliott; Kanta Subbarao; Vera Ignjatovic; Paul Monagle
Journal:  EJHaem       Date:  2022-03-22

Review 2.  Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders.

Authors:  Marta Kaczor-Kamińska; Kamil Kamiński; Maria Wróbel
Journal:  Antioxidants (Basel)       Date:  2022-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.